Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2495023rdf:typepubmed:Citationlld:pubmed
pubmed-article:2495023lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2495023lifeskim:mentionsumls-concept:C0034821lld:lifeskim
pubmed-article:2495023lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:2495023lifeskim:mentionsumls-concept:C0086045lld:lifeskim
pubmed-article:2495023lifeskim:mentionsumls-concept:C0205054lld:lifeskim
pubmed-article:2495023lifeskim:mentionsumls-concept:C0023779lld:lifeskim
pubmed-article:2495023lifeskim:mentionsumls-concept:C0003591lld:lifeskim
pubmed-article:2495023lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:2495023lifeskim:mentionsumls-concept:C1152633lld:lifeskim
pubmed-article:2495023lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:2495023lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:2495023pubmed:issue2lld:pubmed
pubmed-article:2495023pubmed:dateCreated1989-5-15lld:pubmed
pubmed-article:2495023pubmed:abstractTextThe relationships of plasma lipid and apolipoprotein (apo) concentrations to hepatic low-density lipoprotein (LDL) receptor activity were examined in 21 subjects (16 females, 5 males), who were undergoing laparotomy for non-neoplastic disease (cholecystectomy in 16). None had familial hypercholesterolemia, or renal, endocrine or hepatic disease. Ages were 37-77 years (mean, 58 years), plasma cholesterol concentrations 4.09-6.72 mmol/l (5.38) and plasma triacylglycerol concentrations 0.75-2.35 mmol/l (1.36). Receptor activity was quantified in vitro as the total saturable binding and EDTA-suppressible binding (representing apoB,E receptors) of 125I-labelled human LDL (15 micrograms protein/ml) by liver homogenate at 37 degrees C. There were no significant differences between men and women in 125I-labeled LDL binding. In the pooled data, EDTA-suppressible binding averaged 50 ng 125I-LDL protein/mg cell protein (S.D., 15). Total saturable binding averaged 2-fold greater (mean, 101 ng/mg; S.D., 32). Plasma cholesterol, LDL cholesterol and apoB concentrations were negative functions of both EDTA-suppressible binding and total saturable binding, but the correlations with EDTA-suppressible binding were stronger (cholesterol: r = -0.59, P less than 0.01; LDL cholesterol: r = -0.48, P less than 0.05; apoB: r = -0.61, P less than 0.01). Plasma triacylglycerol, high-density lipoprotein cholesterol and apoA-I concentrations were not related to either measure of receptor activity. These results provide evidence that the activity of apoB,E receptors in the liver is a major determinant of the plasma LDL concentration in middle-aged and elderly humans.lld:pubmed
pubmed-article:2495023pubmed:languageenglld:pubmed
pubmed-article:2495023pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:citationSubsetIMlld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2495023pubmed:statusMEDLINElld:pubmed
pubmed-article:2495023pubmed:monthAprlld:pubmed
pubmed-article:2495023pubmed:issn0006-3002lld:pubmed
pubmed-article:2495023pubmed:authorpubmed-author:MillerN ENElld:pubmed
pubmed-article:2495023pubmed:authorpubmed-author:NanjeeM NMNlld:pubmed
pubmed-article:2495023pubmed:issnTypePrintlld:pubmed
pubmed-article:2495023pubmed:day3lld:pubmed
pubmed-article:2495023pubmed:volume1002lld:pubmed
pubmed-article:2495023pubmed:ownerNLMlld:pubmed
pubmed-article:2495023pubmed:authorsCompleteYlld:pubmed
pubmed-article:2495023pubmed:pagination245-55lld:pubmed
pubmed-article:2495023pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:meshHeadingpubmed-meshheading:2495023-...lld:pubmed
pubmed-article:2495023pubmed:year1989lld:pubmed
pubmed-article:2495023pubmed:articleTitleHuman hepatic low-density lipoprotein receptors: associations of receptor activities in vitro with plasma lipid and apolipoprotein concentrations in vivo.lld:pubmed
pubmed-article:2495023pubmed:affiliationDepartment of Chemical Pathology and Metabolic Disorders, St. Thomas' Campus, United Medical School of Guy's Hospital, London U.K.lld:pubmed
pubmed-article:2495023pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2495023pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2495023lld:pubmed